Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$144.95 - $152.29 $261 Million - $274 Million
-1,800,734 Reduced 68.14%
841,900 $127 Million
Q2 2022

Aug 15, 2022

SELL
$83.14 - $145.99 $333 Million - $584 Million
-3,999,905 Reduced 60.22%
2,642,634 $385 Million
Q1 2022

May 16, 2022

BUY
$110.08 - $142.92 $51.1 Million - $66.4 Million
464,530 Added 7.52%
6,642,539 $788 Million
Q4 2021

Feb 14, 2022

BUY
$99.73 - $148.48 $11.5 Million - $17.2 Million
115,628 Added 1.91%
6,178,009 $851 Million
Q3 2021

Nov 15, 2021

BUY
$98.85 - $138.91 $74,532 - $104,738
754 Added 0.01%
6,062,381 $842 Million
Q2 2021

Aug 16, 2021

BUY
$65.78 - $105.02 $86.9 Million - $139 Million
1,321,691 Added 27.88%
6,061,627 $588 Million
Q1 2021

May 14, 2021

BUY
$64.07 - $91.75 $5.8 Million - $8.3 Million
90,488 Added 1.95%
4,739,936 $324 Million
Q4 2020

Feb 12, 2021

BUY
$65.07 - $98.24 $87.2 Million - $132 Million
1,340,473 Added 40.51%
4,649,448 $399 Million
Q3 2020

Nov 13, 2020

BUY
$59.04 - $77.95 $65.6 Million - $86.6 Million
1,110,384 Added 50.5%
3,308,975 $215 Million
Q2 2020

Aug 14, 2020

BUY
$29.01 - $74.23 $21,380 - $54,707
737 Added 0.03%
2,198,591 $161 Million
Q1 2020

May 15, 2020

BUY
$27.51 - $57.29 $15.2 Million - $31.6 Million
551,428 Added 33.49%
2,197,854 $74.8 Million
Q4 2019

Feb 18, 2020

BUY
$40.86 - $57.65 $48.1 Million - $67.8 Million
1,176,426 Added 250.3%
1,646,426 $89.6 Million
Q2 2019

Aug 14, 2019

BUY
$39.79 - $67.01 $18.7 Million - $31.5 Million
470,000 New
470,000 $20.6 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.65B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Capital World Investors Portfolio

Follow Capital World Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital World Investors with notifications on news.